Key result
DES linked to ~69% lower risk of 1-year major events versus BMS in diabetic STEMI.
Why the study?
Diabetic patients experience higher adverse ischemic event and mortality rates after PCI for acute myocardial infarction, suggesting they might derive greater benefit from modern-generation DES.
Does the use of drug-eluting stents reduce adverse ischemic events and mortality compared to bare-metal stents in diabetic patients admitted with STEMI undergoing primary PCI?
Cohort (n=8,356)
Does the use of drug-eluting stents reduce adverse ischemic events and mortality compared to bare-metal stents in diabetic patients admitted with STEMI undergoing primary PCI?
In diabetic patients presenting with STEMI, the use of drug-eluting stents significantly reduces 1-year ischemic events compared to bare-metal stents, effectively lowering their risk to match that of non-diabetic patients.
Answers are grounded in this paper and cite their sources.
May support DES over BMS for ischemic events in diabetic STEMI; leaves open randomized confirmation and mortality effects.
Background: Diabetic patients show higher adverse ischemic event rates and mortality when undergoing percutaneous coronary intervention (PCI) in acute myocardial infarctions. Therefore, diabetic patients might benefit even more from modern-generation drug-eluting stents (DES). The aim of the present study was to compare adverse ischemic events and mortality rates between bare-metal stents (BMS) and DES in diabetic patients admitted with ST-elevation-myocardial infarction (STEMI) with non-diabetic patients as the control group. Methods: All STEMI patients undergoing emergency PCI and stent implantation documented between 2006 and 2019 in the Bremen STEMI registry entered the analysis. Efficacy was defined as a combination of in-stent thrombosis, myocardial re-infarction or additional target lesion revascularization at one year. Results: Of 8356 patients which entered analysis, 1554 (19%) were diabetics, while 6802 (81%) were not. 879 (57%) of the diabetics received a DES. In a multivariate model, DES implantation in diabetics compared to BMS was associated with lower rates of in-stent thrombosis (OR 0.16, 95% CI 0.05–0.6), myocardial re-infarctions (OR 0.35, 95%CI, 0.2–0.7, p < 0.01) and of the combined endpoint at 1 year ((ST + MI + TLR): OR 0.31, 95% CI 0.2–0.6, p < 0.01), with a trend towards lower 5-year mortality (OR 0.56, 95% CI 0.3–1.0, p = 0.058). When comparing diabetic to non-diabetic patients, an elevation in event rates for diabetics was only detectable in BMS (OR 1.78, 95% CI 0.5–0.7, p < 0.01); however, this did not persist when treated with a DES (OR 1.03 95% CI 0.7–1.6, p = 0.9). Conclusions: In STEMI patients with diabetes, the use of DES significantly reduced ischemic event rates and, unlike with BMS, adverse ischemic event rates became similar to non-diabetic patients.
No takes yet. Share an insight, caveat, or question.
Schmucker et al. (2021) conducted a cohort in ST-elevation myocardial infarction (STEMI) and diabetes (n=8,356). Drug-eluting stents (DES) vs. Bare-metal stents (BMS) was evaluated on Combination of in-stent thrombosis, myocardial re-infarction or additional target lesion revascularization at one year (OR 0.31, 95% CI 0.2-0.6, p=< 0.01). Drug-eluting stents reduced 1-year in-stent thrombosis, re-infarction, or target lesion revascularization in diabetic STEMI patients versus bare-metal stents.
Synapse has enriched 10 related papers. Consider them for comparative context: